Average Insider

Where insiders trade, we follow

$CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Healthcare
Sector
Biotechnology
Industry
Samarth Kulkarni
CEO
393
Employees
$42.24
Current Price
$5.24B
Market Cap
52W Low$41.75
Current$42.242.3% above low, 97.7% below high
52W High$63.45

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00--All Sells
Sells11$2,381,325.8647,837
2 monthsBuys00--All Sells
Sells36$4,100,737.8979,879
3 monthsBuys00--All Sells
Sells47$4,881,673.3793,558
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Oct 19, 2026
Kulkarni Samarth
Director
Sale47,837$49.78$2,381,325.86View Details
Oct 14, 2026
George Simeon
Director
Sale14,514$49.63$720,373.36View Details
Oct 14, 2026
KASINGER JAMES R.
General Counsel and Secretary
Sale1,040$49.26$51,230.40View Details
Oct 14, 2026
Kulkarni Samarth
Director
Sale4,098$49.26$201,867.48View Details
Oct 6, 2026
KASINGER JAMES R.
General Counsel and Secretary
Sale1,990$60.04$119,481.19View Details
Sep 22, 2026
KASINGER JAMES R.
General Counsel and Secretary
Sale10,400$60.24$626,459.60View Details
Sep 17, 2026
Behbahani Ali
Director
Sale13,679$57.09$780,935.48View Details
23 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
Feb 11, 2027
EPS
Estimated-$1.17
ActualN/A
Revenue
Estimated$11.34M
ActualN/A

Past Earnings

Historical earnings results
Nov 9, 2026
EPS
Estimated-$1.04
ActualN/A
Revenue
Estimated$14.75M
ActualN/A
Nov 2, 2026
EPS
Estimated-$1.04
Actual-$1.15
Miss
Revenue
Estimated$14.75M
Actual$12.67M
Miss
7 more earnings records available โ€” create a free account to see 12 months of history

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.10.12